Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES - Narrative (Details)

v3.21.2
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
ft²
renewalTerm
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
ft²
renewalTerm
Jun. 30, 2020
USD ($)
Jan. 01, 2022
USD ($)
Dec. 31, 2018
Aug. 31, 2016
Loss Contingencies [Line Items]                
Lease term               5 years
Number of additional terms | renewalTerm 2     2        
Renewal term 3 years     3 years        
Area of leased property | ft² 3,038     3,038        
Monthly payment, initial year $ 4,430     $ 4,430        
Annual payment percentage increase 3.50%     3.50%        
Discount rate 11.00%     11.00%     12.00%  
Expected remaining term 18 months     18 months     2 years 9 months 18 days  
Lease expense $ 23,000   $ 22,000 $ 100,000 $ 100,000      
Research and development 8,838,000   2,712,000 14,890,000 5,376,000      
Forecast                
Loss Contingencies [Line Items]                
Monthly payment, thereafter           $ 6,076    
Bodor Laboratories, Inc.                
Loss Contingencies [Line Items]                
Cash payment       800,000        
Payments for additional product approval       100,000        
Value of shares issued in agreement       1,000,000.0        
Milestone payment     500,000   500,000      
Research and development $ 0 $ 1,000,000.0 $ 1,500,000 $ 0 $ 1,500,000